News Releases

Date Title and Summary
Toggle Summary electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
ROCKAWAY, N.J. , Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman’s World Magazine 50 over 50 Award.
Toggle Summary electroCore Donates gammaCore Sapphire for Real World Evaluation of nVNS in Trauma Among Israelis
ROCKAWAY, N.J. , Nov. 19, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has donated 20 gammaCore Sapphire D’s to be used by Dr. Robin Ely , Director of Integrative and Regenerative Medicine, a
Toggle Summary electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
ROCKAWAY, N.J. , Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New
Toggle Summary electroCore Announces Third Quarter 2024 Financial Results
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA /DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J. , Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary ElectroCore’s Truvaga™ Plus Wins Men’s Health Magazine Tech Award
ROCKAWAY, N.J. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men’s Health Magazine Tech Award for a
Toggle Summary electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J. , Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024 , as the Company’s VP, Corporate Controller.
Toggle Summary electroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
ROCKAWAY, N.J. , Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2024 , after the close of the market on Wednesday,
Toggle Summary electroCore to Participate at LD Micro Main Event VXII
ROCKAWAY, N.J., October 14, 2024  -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the LD Micro Main Event XVII on Tuesday, October 29 at 4:30 p.m.
Toggle Summary electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J. , Sept. 26, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor events:  October 1 - Management will participate in one-on-one meetings at
Toggle Summary electroCore Engages FNK IR to Execute Expanded Investor Relations Program
ROCKAWAY, N.J. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it has engaged FNK IR, an institutionally focused investor relations consulting firm, to develop and deploy an expanded outreach